Eva-Lotta Allan appointed Non-Executive Chairman of the Board
Board further strengthened with the appointment of Natalie Walter
4 July 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that Eva-Lotta Allan and Natalie Walter have been appointed as Non-Executive Chairman of the Board and Non-Executive Director respectively, with immediate effect.
Scientists in Manchester are working on a drug to kill cravings.
After spending his youth hooked on drugs and alcohol, comedian Russell Brand came to a conclusion: addiction is a disease. For him it began with overeating as a child, and by the time he reached young adulthood, Brand had moved on to crack cocaine and heroin. Today, despite being clean for 15 years, the entertainer is adamant that he is still an addict — and that it is a medical condition.
We are delighted to have won the Best Technology Award at the European Mediscience Awards. Thanks to the organisers for a great evening.
Blue skies, streaked with clouds – an unending expanse of grid to stand on – and one massive molecule: in the drug-discovering virtual world, for the first time, scientists can get up close and personal with the drugs they’re designing. Grabbing hold of a virtual molecule, floating in space before them, using two lightsaber-wielding claw-like hands, the chemist can get as close to touching the desired structure as is (meta)physically possible.
“Starting to use VR was quite transformative, because all of a sudden the molecules become part of my world and I can manipulate them in space just ahead of me, like you would do comparing two oranges and two apples,” says Thorsten Nowak, medicinal chemist at C4XD. With the VR platform, drug discovery “became as visual as it can really ever be”.
Clive Dix, chief executive of C4X Discovery Holdings plc (LON:C4XD), discusses with Proactive's Andrew Scott their licensing deal with FTSE 250-listed Indivior for its addiction behaviour suppressant, C4X3256.
It is the first major partnership for C4X, which will receive US$10mln up front and a further US$284mln dependent on how successful the drug proves.
1 May 2018 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that it has entered into a joint research collaboration with e-Therapeutics plc (AIM: ETX) to identify novel mechanistic insights into Parkinson’s Disease (PD). The collaboration utilises both companies’ drug discovery technologies, in particular C4XD’s Taxonomy3® novel target identification platform and ETX’s Network-driven Drug Discovery (NDD) capabilities. Teams from both companies will use the outputs from C4XD’s Taxonomy3® genetic analysis of PD and apply an NDD approach to identify novel intervention strategies which it is expected will lead to new approaches for the treatment of PD.
12 April 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces its interim results for the six months ended 31 January 2018.
C4XD receives $10 million upfront, potential milestones totalling $284 million plus royalties
29 March 2018 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that it has signed a licensing agreement with Indivior UK Limited (LON: INDV, "Indivior") to further develop and commercialise C4XD’s oral Orexin-1 receptor antagonist ("C4X3256") for the treatment of addiction. C4X3256 aims to treat addiction by targeting the "craving" process itself and, therefore, can be applied across a broad range of substance use disorders. The treatment of addiction represents a substantial area of unmet medical need, forecast to be worth an estimated $13 billion per annum in 20181.